© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90622 refers to the Vaccinia (smallpox) virus vaccine, which is a live, lyophilized preparation intended for percutaneous use. This vaccine is designed to provide active, long-term immunity by introducing a modified version of the smallpox virus into the recipient's immune system. The immune system responds by producing antibodies that specifically target the virus, enabling the body to recognize and combat the virus if exposed in the future. Smallpox, caused by the variola virus, is a severe and potentially fatal disease that has been eradicated through vaccination efforts. However, the risk of exposure to different strains of vaccinia remains, particularly for healthcare and laboratory workers who may handle the vaccine or come into contact with infected individuals. The lyophilized form of the vaccine is created through a freeze-drying process that removes moisture from the live virus under controlled vacuum conditions, allowing for safe storage and transport. Prior to administration, the powder must be reconstituted to achieve the correct dosage of 0.3 mL. It is important to note that this code specifically pertains to the vaccine product itself and does not encompass the procedure of administering the vaccine via percutaneous methods.
© Copyright 2025 Coding Ahead. All rights reserved.
The Vaccinia (smallpox) virus vaccine is indicated for individuals who may be at risk of exposure to the smallpox virus, particularly healthcare workers and laboratory personnel who handle the virus or work in environments where exposure is possible. The vaccine is also relevant for individuals involved in research or activities related to orthopoxviruses, including monkeypox, as these viruses share similarities and can pose health risks.
The administration of the Vaccinia (smallpox) virus vaccine involves several key procedural steps to ensure proper dosage and effectiveness. First, the vaccine, which is in a lyophilized form, must be reconstituted. This is done by adding a specific volume of sterile diluent to the vial containing the freeze-dried vaccine powder. The vial is gently swirled to ensure that the powder is fully dissolved, creating a liquid vaccine solution. Once reconstituted, the vaccine is drawn into a syringe, ensuring that the correct dosage of 0.3 mL is prepared for administration. The vaccine is then administered percutaneously, typically using a bifurcated needle, which is dipped into the vaccine solution and then used to puncture the skin in a specific manner to deliver the vaccine into the epidermal layer. This method allows for effective uptake of the vaccine by the immune system. It is crucial that the administration is performed in a controlled environment, following strict aseptic techniques to minimize the risk of infection or complications.
After the administration of the Vaccinia (smallpox) virus vaccine, patients are typically monitored for any immediate adverse reactions, which may include local site reactions such as redness, swelling, or pain. It is important for healthcare providers to educate recipients about potential side effects and the importance of reporting any unusual symptoms. Patients may also be advised to avoid scratching the vaccination site to prevent infection and to keep the area clean and dry. Follow-up appointments may be scheduled to assess the immune response and to provide additional information regarding the vaccine's effectiveness and any necessary precautions. Recipients should be informed about the signs of possible complications and the importance of seeking medical attention if they experience severe reactions.
| Short Descr | VACCINIA VRS VAC 0.3 ML PERQ | Medium Descr | VACCINIA VIRUS VACC LIVE 0.3 ML DOS FOR PERQ USE | Long Descr | Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Nonpass-Through Drugs and Nonimplantable Biologicals, Including Therapeutic Radiopharmaceuticals | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| SL | State supplied vaccine |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2024-01-01 | Added | First appearance in codebook. |
| 2022-07-26 | Added | Published on AMA website 2022-07-26. Received FDA approval effective immediately. |
Get instant expert-level medical coding assistance.